GleamWall
中文EN

ENDV ENDONOVO THERAPEUTICS, INC.

Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 1528172 · Fiscal year ends 12/31

Financial factors as of 2023-09-30 (2023Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,699.9%
TTM net income YoY-40.0%
TTM EPS YoY—
Revenue 3-yr CAGR-5.5%
Net income 3-yr CAGR—

Margins

Gross margin96.2%
Operating margin-1,023.2%
Net margin-1,722.2%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-388.5%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets2,914.6%
Debt / equity—
Current ratio0.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.14x
Accruals ratio-333.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2023Q32023-09-302023Q22023-06-302023Q12023-03-312022Q4*2022-12-312022Q32022-09-302022Q22022-06-302022Q12022-03-312021Q4*2021-12-31
Income statement
Revenue$1,520$45,200$87,540$121,463$10,960$650$2,282$316
Cost of revenue$827$0$3,996$4,866$4,027$383$714$8,861
Gross profit$693$45,200$83,544$116,597$6,933$267$1,568-$8,545
R&D expense———————$0
Operating income-$472,797-$1.13M-$529,290-$483,051-$496,778-$1.80M-$485,762-$373,794
Pretax income-$766,170$2.06M$7.23M-$12.93M-$603,360-$2.53M-$2.41M$2.40M
Net income-$766,170$2.06M$7.23M-$12.93M-$603,360-$2.53M-$2.41M$2.40M
EBITDA-$311,069——-$321,323-$335,050-$1.64M-$324,034-$212,066
EPS (basic)-0.000.000.03—0.00-0.02-0.03—
EPS (diluted)0.00-0.010.00—0.00-0.02-0.03—
Weighted avg. shares (diluted)1.35B1.35B1.74B—153.60M134.36M79.01M—
Banking
Net interest income-$285,892-$312,869-$309,380-$309,326-$338,571-$337,536-$336,142-$227,354
Balance sheet
Cash & equivalents$0$32,602$10,942$98$23,139$0$59,982$85,936
Receivables——$3,120—$944$945$945$944
Current assets$35,504$72,833$95,172$15,822$24,083$5,945$64,427$94,855
Intangibles$780,260$941,988$1.10M$1.27M$1.43M$1.59M$1.75M$1.91M
Total assets$815,764$1.01M$1.20M$1.28M$1.45M$1.59M$1.82M$2.01M
Current liabilities$23.70M$23.14M$25.49M$33.38M$20.98M$20.68M$19.77M$17.70M
Long-term debt$7.09M$7.05M$6.90M$7.15M$7.27M$7.41M$7.35M$7.26M
Total debt$7.09M$7.05M$6.90M$7.15M$7.27M$7.41M$7.35M$7.26M
Total liabilities$23.78M$23.22M$25.57M$33.46M$21.06M$20.75M$19.85M$17.78M
Shareholders' equity-$22.96M-$22.41M-$24.37M-$32.18M-$19.61M-$19.16M-$18.04M-$15.77M
Net debt$7.09M$7.02M$6.89M$7.15M$7.25M$7.41M$7.29M$7.17M
Shares outstanding318.75M278.80M270.29M213.23M159.23M150.43M81.33M74.50M
Cash flow statement
Operating cash flow-$65,367-$165,840-$173,156-$225,541-$123,861-$206,482-$122,954-$391,296
Financing cash flow$32,765$187,500$184,000$202,500$147,000$146,500$97,000$471,500
Depreciation & amortization$161,728——$161,728$161,728$161,728$161,728$161,728
Stock-based compensation$0$3,440$2,560$45,000$0——-$61,000

Free plan shows the latest 8 periods; Pro shows all 49 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.